third-generation anti-cd123 car-t cells
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2019 (NCT04014881)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Interleukin-3 receptor subunit alphaImmunity, passive
IL3RA immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04014881 | Phase 1 | Jul 1, 2019 | Huazhong University of Science and Technology, Wuhan Bio-Raid Biotechnology Co, Ltd. China |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Wuhan Bio-Raid Biotechnology Co, Ltd. China | Government | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1